As filed with the Securities and Exchange Commission on February 28, 2024
Registration No. 333-274005
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
AMPIO PHARMACEUTICALS, INC.
(Exact name of Registrant as specified in its charter)
Delaware | 26-0179592 |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
9800 Mount Pyramid Court, Suite 400 | |
Englewood, Colorado | 80112 |
(Address of Principal Executive Offices) | (Zip Code) |
Ampio Pharmaceuticals, Inc.
2023 Stock and Incentive Plan
(Full title of the plan)
Michael A. Martino
Chief Executive Officer
Ampio Pharmaceuticals, Inc.
9800 Mount Pyramid Court, Suite 400
Englewood, Colorado 80112
(Name and address of agent for service)
(720) 437-6500
(Telephone number, including area code, of agent for service)
With copy to:
April Hamlin
Ballard Spahr LLP
2000 IDS Center
80 South 8th Street
Minneapolis, MN 55402
(612) 371-3211
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.:
Large accelerated filer ◻ | | Accelerated filer ◻ | | Non-accelerated filer þ | | Smaller reporting company þ | | Emerging growth company ◻ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ◻